Today on The Tape Reader: headline financial reporting is completely untethered from underlying run rates this morning. Between Intuit reclassifying its stock-based compensation and Abercrombie banking a non-recurring $100 million tariff refund, trading desks are abandoning optical screening tools and manually unpacking EPS prints to find actual operational momentum.
Abercrombie & Fitch shares jumped 37% to $148.91 after reporting Q2 adjusted EPS of $4.17 versus $1.99 expected. Results were heavily boosted by a $100 million pre-tax IEEPA tariff refund adding $1.75 per share and 220 bps to operating margins (19.9%). Driven by the windfall and 19% APAC sales expansion, management raised FY26 EPS guidance to $13.10-$13.60, despite flat companywide comps and a 3% comp decline at Hollister.
Why it matters
The 37% single-session gapper creates a textbook long-side volume continuation trade, but requires tactical caution due to underlying quality split. While the headline guidance raise and operating margin expansion trap shorts, $1.75 of the $4.17 EPS is a non-recurring tariff refund while core Hollister comps contracted 3%. Active traders should watch for intraday exhaustion near $150; a failure to hold the first 15-minute low signals a gap-fade setup back toward the premarket anchor.
We flagged Intuit's double-digit premarket drop during the broader software sell-off; the underlying driver of its FY27 EPS guidance miss ($22.88-$23.12 versus $27.30 consensus) is a structural accounting change that reclassifies stock-based compensation ($5.81/share) into recurring non-GAAP expenses. FY27 revenue guidance of $23.28B-$23.51B also slightly missed $23.7B estimates due to Mailchimp monetization deceleration.
Why it matters
This represents a classic mechanical mispricing caused by automated algorithms reading headline non-GAAP guidance cuts without factoring in the $5.81 SBC reclassification. While top-line FY27 revenue growth is slowing to 9-10%, the vast majority of the $4.00+ EPS guidance gap is an optical accounting shift rather than cash flow destruction. Swing traders specializing in misread disclosures should monitor for a lower-shadow reversal candle near $320-$335 support to play the mean-reversion snap-back.
Okta shares gapped up 19% in after-hours and premarket trading after reporting Q2 adjusted EPS of $1.05 on $805M in revenue, comfortably topping Wall Street forecasts of $0.97 and $795M. Management subsequently raised full-year revenue and earnings guidance, citing accelerating enterprise adoption of its identity protection suite.
Why it matters
A clean beat-and-raise print paired with a 19% premarket gap provides a high-beta continuation setup in cybersecurity. Following weeks of software factor de-grossing, Okta's guidance raise demonstrates resilient enterprise IT security spend. Traders should benchmark $95-$100 as the primary breakout level; holding above premarket VWAP on the opening drive confirms short-covering transitioning into institutional trend-following.
We tracked Zoom's 5.8% premarket drop alongside Intuit; the sell-off was triggered by Q3 adjusted EPS guidance of $1.46-$1.48, missing the $1.50 consensus estimate. The guidance caution overshadowed solid Q2 results where revenue grew 4.9% to $1.28B and adjusted EPS hit $1.55 (vs. $1.44 expected). Enterprise revenue accelerated to 7.8% YoY—its fastest rate in three years—while online segment revenue stagnated at +0.6%.
Why it matters
Zoom's selloff highlights the extreme market sensitivity to micro-guidance misses (-2% at the midpoint) in transitional tech names. The structural story shows clear divergence: enterprise AI companion upgrades are working (+7.8% growth), but legacy online retail subs are dragging cash conversion (-7% FCF). Active intraday traders can target $94.00 support for a gap-fill trade if short-sellers exhaust opening volume.
Revolution Medicines secured FDA clearance on Wednesday, August 26, for its oral RAS inhibitor Rasonque (daraxonrasib) in metastatic pancreatic adenocarcinoma, arriving months ahead of schedule via Breakthrough Therapy status. Phase 3 trial data showed a median overall survival of 13.2 months versus 6.7 months for chemotherapy, cutting mortality risk by 60% (HR 0.40). The stock extended its 165% YTD advance on expanding relative volume.
Why it matters
Early FDA approval converts RVMD from a speculative clinical platform into a commercial-stage oncology leader with immediate prescription revenue. The 60% reduction in mortality risk provides a clear efficacy moat that de-risks pipeline expansions into lung and colorectal RAS-mutated cancers. Traders should monitor opening volume signatures for a high-volume breakout over prior 52-week highs, using the $222.89 sell-side target cluster as an upside reference point.
Meta Platforms agreed to pay up to $18 billion over 10 years to resolve child safety and addiction lawsuits brought by nearly all U.S. states, lifting equity shares over 4% toward $580. The agreement mandates product changes—including a default two-hour daily limit for minors and overnight notification blocks—while guaranteeing $12.7B in base payments. Concurrent news showed Evercore raising its PT to $860.
Why it matters
The $18B settlement removes an existential multi-year legal trial overhang for Meta at a cash cost representing roughly four months of net income. While mandatory teen engagement limits introduce minor long-term ad inventory drag, the resolution frees institutional capital to focus on Meta's October 'Watermelon' AI model and 'Hatch' agent platform launches. The relief rally provides swing desks with a clean breakout setup over $575 resistance.
Salesforce reported Q2 adjusted EPS of $5.90 versus the $3.27 consensus estimate on revenue of $11.35B. Management raised fiscal 2027 revenue guidance to $46.1B-$46.4B and highlighted a 240% jump in annualized revenue from its Agentforce AI products to $1.5B, alongside a $2.6B valuation gain from its Anthropic stake. CEO Marc Benioff directly countered SaaS disintermediation bear cases, and the stock gapped up over 13% premarket, clearing multi-week resistance.
Why it matters
This report provides a massive fundamental anchor for an episodic pivot out of a multi-month base. The $2.63 EPS surprise and 240% surge in Agentforce ARR directly challenge the market's ongoing SaaS-liquidation thesis, demonstrating that enterprise AI workloads drive incremental seat and data-cloud monetization. For swing traders, the gap clears overhead supply from the mid-$200s, creating an opening-drive setup where hold-above-VWAP action favors multi-day trend continuation.
The J.M. Smucker Company lifted its fiscal 2027 adjusted EPS guidance to $10.50-$11.00 (from $9.75-$10.25), easily beating the $10.05 Wall Street consensus. SJM also raised its sales target to $8.87B-$8.96B against $8.76B expected. Shares traded up over 3% on expanding daily relative volume, breaking out of a multi-week consolidation channel.
Why it matters
In a tape where software multiples are getting sliced on growth deceleration, consumer staples raising forward EPS guidance by nearly 8% at the midpoint draw immediate defensive momentum flows. SJM's margin expansion proves pricing power and supply-chain efficiency without sacrificing volume. The breakout past its mid-$120s consolidation offers swing traders a low-beta, high-probability long setup with defined invalidation below $125.
TTM Technologies reported Q2 non-GAAP EPS of $0.99 (vs. $0.90 expected) on $1.0B in revenue (+37% YoY). Management aggressively raised Q3 EPS guidance to $1.21-$1.27 and established FY26 targets of $5.00 EPS on $4.4B revenue. Concurrently, TTMI announced an all-cash $1.1B acquisition of EPIQ Design Solutions to expand high-margin RF and software-defined radio capabilities.
Why it matters
TTMI is executing a classic dual-catalyst pivot: organic beat-and-raise momentum paired with transformational M&A. Acquiring EPIQ accelerates TTM's margin expansion into defense electronics and advanced RF hardware, providing a multi-year re-rating thesis. With price expanding out of a $110-$140 base on expanding volume, swing traders have a clear breakout structure backed by sell-side target hikes.
SolarEdge Technologies surged 8% to $32.22 after UBS upgraded the stock to Buy from Neutral and raised its price target to $42 from $36. The catalyst is a fresh FCC ruling placing foreign-produced connected inverters on its Covered List, effectively banning new imports that currently comprise roughly 50% of the domestic market and forcing utility customers toward SEDG's 330kW TerraMax inverter.
Why it matters
Regulatory import bans create immediate supply voids that allow domestic incumbents to capture market share independently of broad sector demand. SolarEdge has been heavily beaten down (down 58% over three months), making this FCC ruling an ideal catalyst for an episodic pivot out of a multi-month capitulation base. The sharp divergence against neutral peers like ENPH highlights focused institutional flow targeting a clear domestic supply-chain moat.
VCI Global shares dropped 8.8% to $2.59 on Wednesday, August 26, completing a textbook parabolic unwind after surging from sub-$0.30 to premarket highs above $5.00. Despite holding $116.9M in assets and a reported book value near $75.97 per share, the extreme low-float structure fueled violent retail momentum before heavy intraday profit-taking pinned price near the $2.50 VWAP shelf.
Why it matters
VCIG provides a classic case study in low-float exhaustion setups where fundamental balance sheet metrics (a deep discount to book value) are irrelevant during climactic retail squeezes. The rejection above $5.00 on massive relative volume marks the blow-off top, transitioning the ticker into a day-trader short setup on any weak VWAP bounces. Risk invalidates strictly above the $2.70 intraday high-volume node.
The Bureau of Economic Analysis reported Wednesday that the July PCE price index rose 0.2% M/M and 3.7% Y/Y, topping the 3.6% consensus estimate, while core PCE held steady at 3.3% Y/Y. Real Q2 GDP growth was unrevised at 1.5% annualized. Treasury yields nudged higher across the front end, and September Fed rate hike probabilities ticked toward 36%-40%.
Why it matters
A 3.7% headline PCE print keeps inflationary pressure alive and prevents front-end Treasury yields from easing ahead of Chair Kevin Warsh's Jackson Hole address on Friday. For trading desks, sticky inflation caps index-level valuation multiples and maintains a tight rangebound structure on SPX (7,636-7,697). Position sizing should remain tactical, favoring single-stock idiosyncratic catalysts over broad beta exposure.
Non-GAAP Accounting Shifts Trigger Algorithmic Premarket Mispricing Structural reclassifications of stock-based compensation (SBC) into recurring expenses are creating artificial guidance misses in software leaders, opening high-conviction snap-back opportunities for manual desks.
Regulatory Import Curbs Establish Domestic Hardware Moats FCC covered-list additions and supply restrictions against foreign component makers are generating sudden supply-side vacuums that instantly re-price beaten-down domestic equipment manufacturers.
Accelerated Priority Approvals Re-Anchor Biotech Platform Valuations Early FDA clearances and priority review grants for oral small molecules and targeted RAS inhibitors are driving multi-billion-dollar market cap re-ratings independent of broad equity tape headwinds.
Severe Guidance Multiplier Penalties Target SaaS Enterprise Deceleration Institutional flow is enforcing zero tolerance for minor forward EPS or top-line misses in software, triggering immediate double-digit liquidation events even on headline beat-and-raise quarters.
Macro Stagflation Crosscurrents Anchor Index Options Rangebounds Hot headline PCE figures paired with unrevised GDP prints are capping broad index upside, concentrating daily alpha inside high-relative-volume single-stock gappers and episodic pivots.
What to Expect
2026-08-27—Gilead Sciences (GILD) PDUFA action date for once-daily HIV combination BIC/LEN.
2026-08-27—IREN Limited reports post-market earnings with emphasis on AI data-center contract conversion.
2026-08-28—Fed Chair Kevin Warsh delivers inaugural keynote address at the Jackson Hole Economic Symposium.